Medica Jadertina, Vol. 48 No. 1-2, 2018.
Izvorni znanstveni članak
Argon plasma coagulation as therapy in treatment of Barret's esophagus
Melanija Ražov Radas
orcid.org/0000-0003-4530-4350
; Opća bolnica Zadar, Služba za internu medicinu, Odjel za gastroenterologiju
Sažetak
The aim of this study was to evaluate the effect of argon plasma coagulation (APC) in the treatment of Barrett’s esophagus (BE) and confirm the expression of Mucin 2 glycoprotein (MUC2) and Vascular Endothelial Growth Factor (VEGF) in Barrett’s mucosa before and/or after APC treatment. A higher expression of MUC2 and VEGF in Barrett's mucosa may be associated with a higher risk for the development of adenocarcinoma (AC). The study included five patients with diagnosis of BE, short-segment. The inclusion criteria was unsuccessful treatment with proton pump inhibitors (PPI). The diagnosis was confirmed by patohystological (PH) analysis after EGJ biopsy. The expression of MUC2 and VEGF was performed with immunohistochemistry. After various APC treatments, the complete recovery of EGJ mucosa occurred in IM patients. The recovery was not achieved in patients with dysplastic change of tissue. There were no malignant developments. These patients remained on PPI therapy and regular endoscopic control. We found histological regression of BE in Gastroesophageal reflux disease (GERD) in four patients. The patients informed us about their clinical improvement: they had less, or completely no symptoms of regurgitation, burning phenomenon and dyspepsia that were leading symptoms due to which they were brought to our hospital.
Ključne riječi
Barrett's esophagus; argon plasma coagulation; proton pump inhibitors
Hrčak ID:
197845
URI
Datum izdavanja:
27.3.2018.
Posjeta: 2.163 *